Scott DindotExecutive Director of Molecular Genetics at Ultragenyx PharmaceuticalSpeaker
Agenda Sessions
Preclinical Development Of An Investigational ASO Targeting The UBE3A-AS Transcript For The Treatment Of Angelman Syndrome
, 12:10pmView Session